Induction chemotherapy in Barrett cancer: Influence on surgical risk and outcome

Annals of Surgery

Volumn 246, Issue 4, 2007, Pages 624-628

  Siewert, Joerg R ^a   Lordick, Florian ^a   Ott, Katja ^a   Stein, Hubert J ^b   Weber, Wolfgang A ^c   Becker, Karen ^d   Peschel, Christian ^a   Fink, Ulrich ^a   Schwaiger, Markus ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b PARACELSUS MEDICAL UNIVERSITY   (Austria)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ADULT; ARTICLE; BLEEDING; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; HEART DISEASE; HUMAN; INFECTION; LUNG DISEASE; MAJOR CLINICAL STUDY; METABOLISM; NECROSIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REMISSION; SEPSIS; SPLEEN RUPTURE; SURGICAL RISK; THROMBOEMBOLISM; TREATMENT OUTCOME; TUMOR GROWTH; ULTRASOUND;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BARRETT ESOPHAGUS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; ESOPHAGOGASTRIC JUNCTION; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RADIOPHARMACEUTICALS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34748814302     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/SLA.0b013e318155a7d1     Document Type: Article

References (22)

1. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol. 2001;19:3058-3065.
2. Ott K, Weber WA, Lordick F, et al. Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction. J Clin Oncol. 2006;24:4692-4698.
3. Wieder HA, Beer AJ, Lordick F, et al. Comparison of changes in tumor metabolic activity and tumor size during chemotherapy of adenocarcinomas of the esophagogastric junction. J Nucl Med. 2005;46:2029-2034.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11-20.
5. Medical Research Council Oesophageal Cancer Working Party. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 2002;359:1727-1733.
6. Gebski V, Burmeister B, Smithers BM, et al. Survival benefits from neoadjuvant chemoradiatherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007;8:226-234.
7. Siewert JR, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457-1459.
8. Bartels H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg. 1998;85:840-844.
9. Stein HJ, Feith M, Siewert JR. Individualized surgical strategies for cancer of the esophagogastric junction. Ann Chir Gynaecol. 2000;89:191-198.
10. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer. 2003;98:1521-1530.
11. Sarbia M, Becker KF, Hofler H. Pathology of upper gastrointestinal malignancies. Semin Oncol. 2004;31:465-475.
12. Ilson DH. Cancer of the gastroesophageal junction: combined modality therapy. Surg Oncol Clin N Am. 2004;15:803-824.
13. Das P, Fukami N, Ajani JA. Combined modality therapy of localized gastric and esophageal cancers. J Natl Compr Canc Netw. 2004;4:375-382.
14. Chong G, Cunningham D. The role of preoperative chemotherapy for esophageal cancer: when is surgery alone feasible? Nat Clin Pract Oncol. 2005;2:172-173.
15. Lordick F, Stein HJ, Peschel C, et al. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540-551.
16. Hardwick RH, Williams GT. Staging of oesophageal adenocarcinoma. Br J Surg. 2002;89:1976-1077.
17. Kelly S, Harris KM, Berry E, et al. A systematic review of the staging performance of endoscopic ultrasound on gastro-oesophageal carcinoma. Gut. 2001;49:534-539.
18. Rösch T. Endosonographic staging of esophageal cancer: a review of literature results. Gastrointest Endosc Clin N Am. 1995;5:537-547.
19. van Westreenen HL, Westerterp M, Bossuyt PM, et al. Systematic review of the staging performance of 18F-fluorodeoxyglucose positron emission tomography in esophageal cancer. J Clin Oncol. 2004;22:3805-3812.
20. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984.
21. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery compared to surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167.
22. Fiorica F, Di Bona D, Schepis F, et al. Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut. 2004;53:925-930.